Search Results

Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer, Professor Deane is one of the UK’s most accomplished bioinformaticians. Prior to this, Professor Deane was Deputy Executive Chair of the Engineering and Physical Sciences Research Professor Deane holds a B.A. in Chemistry from the University of Oxford and a Ph.D. in Biochemistry from

.- Jan Steyaert, scientific director of the VIB-VUB Center for Structural Biology, Vlaams Instituut Biotechnologie Jan Steyaert will be presented with the Gabbay Award at Brandeis University on October 27 when he will

Pierre Eftekhari, Dr. Lauren Slosky, Dr. Christel Menet, Dr. Ben Myers and Dr. Niña Caculitan.

The biological validation came from Jean-Philippe Pin’s group at the Genomic Functional Institute in

layered collaborations—with Durham University chemist David Parker on the probe chemistry, and with Jean-Philippe

→ Discovery of pH-sensitive dual response (brightness + lifetime) → Application to GPCR models with Jean-Philippe

Kawthar Belkacemi, Philippe Rondard, Jean-Philippe Pin, and Laurent Prézeau, for their research on Heterodimers

$8.7 billion FDA approves two gene therapies for sickle cell disease, including first that uses CRISPR Pier

Nature 557, 452–456. https://doi.org/10.1038/s41586-018-0077-3 Pierce, K.L., and Lefkowitz, R.J. (2001

They’re kinetic game-changers —compounds that rewrite the relationship between ligand , receptor , and In this lesson, you'll gain: ✅ Clarity on what “irreversible” really means  in kinetic and pharmacologic For discovery teams, this means a shorter exposure can yield longer efficacy windows—opening doors to This PK/PD dissociation  means: Drug exposure may end, but receptor occupancy remains. This reframes what it means to characterize potency.

Changeux J-P, Christopoulos A.